ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2033-04-30
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investigate using circulating tumor DNA (ctDNA) at pre-determined time points using Foresight CLARITY LDT, an ultra-sensitive liquid biopsy platform that detects Minimal residual disease (MRD) in patients with B-cell lymphomas using the phased variant enrichment and sequencing technology (PhasEDq) to determine response to study interventions.
Phase:
PHASE2
Details
Lead Sponsor:
Michael Spinner, MD
Collaborators:
Foresight Diagnostics Gateway for Cancer Research UC Hematologic Malignancies Consortium (UCHMC)